NPPA Drug Price Notification November 2026 - New Medicine Prices and Compliance Rules
Quick note
Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.
Schedule a Call Back
Businesses we've worked with on drug licence
Clients include Cure and Care Wellness, 1008 Digital Health, Nfilade Security Solutions, Evoq Technologies, Kantika Import Export and Trading, Rock Well Industries, Abhay Healthtech, Hind Svasthya Healthcare, Pridus Global Pharma, Arka Brenstech, Believe Cosmetics, Imedicndr Healthcare (12 of 40+ served since 2018).
A few more clients we've served in this industryHide the list
- Clients include
- Cure and Care Wellness · 1008 Digital Health · Nfilade Security Solutions · Evoq Technologies · Kantika Import Export and Trading · Rock Well Industries · Abhay Healthtech · Hind Svasthya Healthcare · Pridus Global Pharma · Arka Brenstech · Believe Cosmetics · Imedicndr Healthcare · Katre Enterprises · Soapsquare Healthcare · Xsourcee
Summary
The National Pharmaceutical Pricing Authority (NPPA) has made four Orders on 2nd November 2026 under the Drugs (Prices Control) Order, 2013. The Orders pertain to various drugs including tablets, injections, oral suspension, capsules, eye drops and gels.
The NPPA drug price notification November 2026 fixes retail prices for 35 drug formulations, revises the ceiling price of Oxaliplatin injection and corrects certain entries in a 2018 notification.
These orders matter to pharmaceutical manufacturers, marketing companies and businesses selling the affected medicines. Companies must check whether their products are covered and ensure that their prices follow the conditions stated in the relevant notification.
NPPA Drug Price Notifications November 2026 at a Glance
The four orders have varying objectives. Two determine retail prices of designated formulations, one modifies a ceiling price, and the other rectifies an earlier notification.
The notifications do not mean that the prices of all medicines have changed. Each order applies to the products and conditions mentioned in it.
| Notification | Main subject | Key affected products | Nature of the order |
| S.O. 5998(E) | Retail price fixation | 34 specified drug formulations | Manufacturer/formulation-specific price entries |
| S.O. 5999(E) | Retail price fixation | Cholecalciferol 7,000 IU tablet | One notified retail price |
| S.O. 6001(E) | Ceiling price revision | Oxaliplatin 5 mg/mL, 10 mL vial | Scheduled-formulation ceiling price |
| S.O. 6002(E) | Corrigendum | Specified Diclofenac, Methyl Salicylate and Menthol gel entry and deleted serial numbers | Correction to 2018 order |
Companies reviewing the NPPA latest notification November 2026 should identify the order relevant to their specific formulation before updating product pricing.
Regulatory Framework Under the Drugs (Prices Control) Order, 2013
Medicine prices in India are regulated under the Drugs (Prices Control) Order, 2013, commonly called DPCO 2013. The order was issued under the Essential Commodities Act, 1955.
The National Pharmaceutical Pricing Authority is responsible for implementing the relevant provisions of DPCO 2013. It fixes or revises prices for specified medicines and takes action in cases where applicable price limits are not followed.
The November 2026 notifications have been issued under this existing legal framework.
Role of the National Pharmaceutical Pricing Authority
NPPA fixes ceiling prices for scheduled drug formulations and retail prices for certain new drug formulations covered by DPCO 2013.
It also monitors compliance with drug pricing requirements and deals with overcharging matters under the applicable law.
For pharmaceutical companies, an NPPA notification is important because it may affect the price at which a covered medicine can be sold.
Legal Basis for Retail Price Fixation
S.O. 5998(E) and S.O. 5999(E) were issued under paragraphs 5, 11 and 15 of DPCO 2013, read with the relevant government orders and amendments.
These orders fix retail prices for the formulations mentioned in their tables. The notified price is linked to the particular medicine, its composition, strength, unit and identified manufacturer or marketing company.
Legal Basis for Ceiling Price Revision
S.O. 6001(E) concerns Oxaliplatin injection. It was issued following directions contained in a review order under paragraph 31 of DPCO 2013.
The notification also considers the Wholesale Price Index (WPI) impact of 0.64956% for 2026.
The revised ceiling price applies to the specified Oxaliplatin formulation and unit. It should not be treated as a common price for every Oxaliplatin product available in the market.
What Has Changed Under the NPPA Drug Price Notifications?
The November orders deal with three main developments: new retail-price fixation for identified formulations, revision of an existing ceiling price and correction of an earlier pricing notification.
NPPA Fixes Retail Prices for 34 Drug Formulations
Under S.O. 5998(E), NPPA has fixed retail prices for 34 formulations. These include medicines containing Paracetamol, Metformin, Sitagliptin, Moxifloxacin, Ondansetron, Methylprednisolone and other ingredients.
The list also includes combination medicines used in different treatments.
Each entry gives the medicine name, composition, strength, pricing unit, manufacturer or marketing company and notified retail price.
The notified amount is not a general price for all medicines containing the same ingredient. It is important to match the exact formulation with the details given in the order.
Retail Price Fixed for Cholecalciferol 7,000 IU Tablets
Under S.O. 5999(E), NPPA has fixed the retail price of Cholecalciferol 7,000 IU chewable tablets at ₹8.93 per tablet, excluding applicable GST.
The order identifies Windlas Biotech Limited as the manufacturer and Eris Lifesciences Limited as the marketing company.
The notified retail price applies to the specified product and the manufacturer–marketing company arrangement covered by the order.
Ceiling Price Revised for Oxaliplatin Injection
S.O. 6001(E) revises the ceiling price for Oxaliplatin injection, 5 mg/mL in a 10 mL vial.
The earlier ceiling price listed in the notification was ₹2,287.59 per vial. The revised price is ₹2,285.84 per vial, excluding applicable GST.
The change represents a reduction of ₹1.75 per vial compared with the earlier amount shown in the notification.
Although the revised price takes the 2026 WPI impact into account, it also reflects the directions of the review order mentioned by NPPA. Therefore, the final revised price is lower than the earlier listed amount.
Correction to an Earlier NPPA Price Notification
Through S.O. 6002(E), NPPA has corrected certain entries in S.O. 5638(E), dated 2 November 2018.
The revised entry at serial number 35 relates to Diclofenac, Methyl Salicylate and Menthol gel marketed by Sun Pharmaceutical Industries Limited.
The corrected retail price is ₹6.25 per gram.
The corrigendum also deletes serial numbers 36, 51 and 52 from the table of the earlier notification.
The remaining notes and other contents relating to serial number 35 continue unchanged. This correction must be read with the original 2018 order.
The NPPA drug price fixation orders therefore need to be read individually. The retail-price entries, the Oxaliplatin ceiling-price revision and the 2018 corrigendum do not impose identical obligations.
List of Medicines Covered Under the NPPA Retail Price Notification 2026
S.O. 5998(E) contains 34 drug formulations with notified retail prices. The medicines include tablets, oral liquids, injections, capsules, eye drops, gels and other preparations.
The table below lists the formulation names, pricing units and retail prices stated in the Gazette.
NPPA Retail Price List Under S.O. 5998(E)
| No. | Drug formulation (shortened) | Notified unit | Retail price (₹, excluding applicable GST) |
| 1 | Alginate raft-forming oral suspension BP | 1 mL | 0.97 |
| 2 | Amoxicillin and Potassium Clavulanate oral suspension | 1 mL | 5.10 |
| 3 | Benfotiamine, Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Chromium Picolinate, Myo-Inositol and Pyridoxine tablets | 1 tablet | 24.01 |
| 4 | Ceftriaxone and Tazobactam injection | 1 vial | 125.07 |
| 5 | Ciprofloxacin and Dexamethasone eye drops | 1 mL | 2.71 |
| 6 | Doxylamine Succinate and Pyridoxine Hydrochloride extended-release tablets | 1 tablet | 13.14 |
| 7 | Gemcitabine injection, 1.4 g/36.84 mL | 1 vial | 5,623.07 |
| 8 | Gentamicin Sulphate and Dexamethasone Sodium Phosphate eye/ear drops | 1 mL | 1.75 |
| 9 | Ibuprofen and Paracetamol suspension | 1 mL | 0.60 |
| 10 | Metformin extended-release and Sitagliptin tablets | 1 tablet | 13.92 |
| 11 | Methotrexate oral solution | 1 mL | 12.70 |
| 12 | Methylprednisolone 4 mg tablets | 1 tablet | 5.30 |
| 13 | Methylprednisolone 16 mg tablets | 1 tablet | 10.28 |
| 14 | Moxifloxacin eye drops IP | 1 mL | 35.37 |
| 15 | Moxifloxacin Hydrochloride and Dexamethasone Phosphate eye drops | 1 mL | 20.40 |
| 16 | Multivitamin and multi-mineral drops | 1 mL | 3.20 |
| 17 | Myo-Inositol and Metformin Hydrochloride SR tablets | 1 tablet | 24.45 |
| 18 | Paracetamol and Mefenamic Acid suspension | 1 mL | 0.95 |
| 19 | Paracetamol and Caffeine tablets | 1 tablet | 3.84 |
| 20 | Rosuvastatin 20 mg, Aspirin and Clopidogrel capsules | 1 capsule | 25.21 |
| 21 | Rosuvastatin 10 mg, Aspirin and Clopidogrel capsules | 1 capsule | 16.56 |
| 22 | Tranexamic Acid and Mefenamic Acid tablets | 1 tablet | 35.81 |
| 23 | Vitamin D3 (Cholecalciferol) drops | 1 mL | 6.36 |
| 24 | Paracetamol injection, 1,000 mg/4 mL | 1 vial | 341.26 |
| 25 | Ondansetron 2 mg orally disintegrating strips | 1 strip | 15.90 |
| 26 | Ondansetron 4 mg orally disintegrating strips | 1 strip | 17.25 |
| 27 | Diclofenac Diethylamine, Methyl Salicylate and Menthol gel | 1 gram | 4.09 |
| 28 | Diclofenac Sodium and Paracetamol tablets | 1 tablet | 5.92 |
| 29 | Clarithromycin, Vonoprazan and Amoxicillin combikit | 1 strip | 118.52 |
| 30 | Vonoprazan and Amoxicillin combikit | 1 strip | 50.53 |
| 31 | Vonoprazan, Clarithromycin and Amoxicillin combikit | 1 combipack | 122.34 |
| 32 | Bisoprolol 2.5 mg, Telmisartan and Cilnidipine tablets | 1 tablet | 19.11 |
| 33 | Bisoprolol 5 mg, Telmisartan and Cilnidipine tablets | 1 tablet | 20.87 |
| 34 | Carbimazole 2.5 mg tablets | 1 tablet | 1.34 |
Source: S.O. 5998(E), dated 2 November 2026. Prices exclude applicable GST. Formulation names are shortened for readability; the complete composition, strength and manufacturer details in the Gazette determine applicability.
Why the Exact Drug Composition Matters
A medicine's name alone is not enough to decide whether the notified price applies.
Two products may contain the same main ingredient but have different strengths, combinations or dosage forms.
For instance, the notification gives separate retail prices for Ondansetron 2 mg and 4 mg orally disintegrating strips. It also provides different prices for the Rosuvastatin combinations containing 10 mg and 20 mg strengths.
Pharmaceutical manufacturers and marketing companies should therefore check the entire formulation entry, not just the first ingredient.
The named manufacturer and marketing company are also important. The scope of a retail-price fixation order may be limited to particular manufacturers, subject to the conditions governing other manufacturers launching the same new drug.
Retail Price Under S.O. 5999(E)
The Cholecalciferol order contains one separate formulation.
| Formulation | Strength | Manufacturer | Marketing company | Unit | Retail price (₹) |
| Cholecalciferol chewable tablet | 7,000 IU | Windlas Biotech Ltd. | Eris Lifesciences Ltd. | 1 tablet | 8.93 |
This price is specific to the formulation and the named company arrangement covered by the notification.
Revised Oxaliplatin Ceiling Price Under S.O. 6001(E)
| Formulation | Unit | Earlier listed ceiling price (₹) | Revised ceiling price (₹) | Difference |
| Oxaliplatin injection, 5 mg/mL in a 10 mL vial | 1 vial | 2,287.59 | 2,285.84 | ₹1.75 lower |
The prices in this NPPA ceiling price notification are stated exclusive of applicable GST.
The revised ceiling price is ₹1.75 lower than the earlier figure.
Manufacturers covered by this notification must check their existing MRPs against the revised ceiling price and apply the relevant DPCO conditions.
Difference Between Ceiling Price and Retail Price Under DPCO 2013
NPPA uses the terms ceiling price and retail price in different pricing situations.
A ceiling price is the maximum price fixed for a scheduled formulation under the relevant DPCO provisions.
A retail price may be fixed for a specified new drug formulation and may be linked to the identified manufacturer or marketing company.
| Comparison | Ceiling price | Retail price |
| Relevant products | Scheduled formulations covered by the order | Specified new-drug formulations covered by the order |
| Main purpose | Applicable upper price limit | Notified retail-price fixation |
| Scope | Determined by the scheduled formulation and governing rules | May depend on named manufacturer, marketer, strength and unit |
| Pack price | Governed by applicable DPCO pack-pricing requirements | Governed by applicable DPCO pack-pricing requirements |
This distinction is important when seeking DPCO 2013 compliance advice or reviewing medicine MRP compliance.
Businesses should first identify which type of order applies to their product. This helps avoid using the wrong price or applying conditions that belong to a different notification.
Which Pharmaceutical Companies Are Affected by the NPPA Notifications?
The November 2026 notifications do not apply in the same way to every pharmaceutical business.
Their effect depends on the medicine, formulation, strength, manufacturer, marketing company and the conditions stated in the relevant order.
Pharmaceutical Manufacturers
Manufacturers of covered formulations must follow the applicable notified prices.
For Oxaliplatin injection, the ceiling-price notification requires manufacturers selling above the permitted ceiling price, plus applicable GST, to revise their prices downward.
Manufacturers whose existing MRPs are below the notified ceiling price plus applicable GST must continue maintaining those lower prices as required under paragraph 13(2) of DPCO 2013.
Pharmaceutical Marketing Companies
Marketing companies named in a retail-price order must check whether the products they market match the notified formulation and price.
They should coordinate with the manufacturer whenever pricing records, labels or other relevant documents need to be updated.
The applicable legal responsibilities must be determined from the specific notification and governing provisions.
Companies Planning to Launch the Same New Drug
S.O. 5998(E) contains a condition for other existing manufacturers launching the same specified new drug within twelve months of Gazette publication.
Such manufacturers may market the formulation at a price not exceeding the notified retail price, subject to filing Form IA through IPDMS 2.0 with supporting documents within one month of launch.
The conditions of this particular order must be checked before relying on the provision.
Pharmaceutical Distributors and Retailers
Drug distributors and retailers should check the updated price lists supplied by manufacturers.
Retailers and dealers must also meet the relevant display requirements under paragraph 24(4) of DPCO 2013.
The obligation is not to change the prices of every medicine in stock. Businesses need to identify the particular products covered by the relevant notification.
Impact of NPPA Revised Drug Prices 2026 on Pharmaceutical Businesses
The direct impact of the November notifications is on the pricing of the covered medicines. Businesses may also need to review related records and reporting requirements.
Changes to Product Pricing
Manufacturers should compare their existing prices with the applicable notified retail or ceiling price.
Where a change is required, the company must ensure that the new price follows the relevant DPCO provisions.
For products with different strengths or pack sizes, each relevant formulation should be reviewed separately.
Review of MRP and Packaging Information
The price printed on a medicine pack must comply with the applicable pricing requirements.
When a government price order affects an existing product, manufacturers should check the corresponding pack MRP and determine what changes, if any, are required under the law.
The notified price must be read together with the applicable unit, pack-pricing rules and GST treatment.
Coordination Between Manufacturers and Marketing Companies
Some formulations are manufactured by one company and marketed by another.
In these cases, both parties need accurate information about the relevant product, notified price and applicable regulatory responsibilities.
Maintaining consistent pricing records can help avoid differences between manufacturing documents, marketing information and product labels.
Compliance Records and Reporting
The relevant DPCO provisions may require submission of price lists, production or sales returns, or other specified forms.
Pharmaceutical companies should identify which forms apply to their products and ensure that relevant submissions are made within the prescribed time.
Drug Pricing Compliance Requirements Under DPCO 2013
Drug price compliance involves more than checking the notified amount. The relevant orders also refer to price lists, reporting and other conditions.
However, not every requirement applies to every manufacturer. Each company must check the specific order governing its formulation.
Submission of Price Lists Through IPDMS
The November orders refer to the price-list requirements under paragraph 24 of DPCO 2013.
Concerned manufacturers must issue the applicable price list in Form V and submit it to NPPA through the Integrated Pharmaceutical Database Management System (IPDMS).
Copies must also be provided to the State Drug Controller and dealers, as required by the relevant order.
The price list must reflect the correct notified price and product details.
Form IA Filing for New Drug Launches
S.O. 5998(E) contains a provision for other existing manufacturers launching the same new drug covered by the order.
Where the stated conditions are satisfied, Form IA must be filed through IPDMS 2.0 within one month of launch, along with the required supporting documents.
Companies should confirm that the formulation, strength and unit match the notified entry before applying this provision.
Quarterly Reporting of Production, Import and Sales
The Oxaliplatin notification contains reporting requirements for manufacturers of the covered scheduled formulation.
The order refers to quarterly returns in Form III of Schedule II of DPCO 2013, covering production, import and sale of the formulation.
These reporting requirements should not be described as new duties automatically imposed on every medicine listed in the November retail-price notifications.
Reporting Before Discontinuing Production
The Oxaliplatin order also refers to the requirements for manufacturers intending to discontinue production or import of the covered scheduled formulation.
Under the applicable provision, the concerned manufacturer must furnish information in Form IV of Schedule II at least six months before the intended discontinuation.
A manufacturer planning to stop producing or importing a covered formulation should examine the relevant conditions before taking that step.
Pharmaceutical Compliance Requirements at a Glance
| Requirement | Responsible entity | Relevant form or provision | Condition or timing |
| Comply with notified price | Covered manufacturer or marketer | Applicable NPPA order | According to product-specific scope |
| Issue and submit price list | Concerned manufacturer | Form V, DPCO paragraph 24 | As required from notification under the relevant order |
| Launch the same specified new drug | Qualifying existing manufacturer under S.O. 5998(E) | Form IA on IPDMS 2.0 | Within one month of launch, subject to the order |
| Quarterly production/import/sales return | Manufacturers of the covered scheduled formulation | Form III, Schedule II | Quarterly |
| Notice before discontinuation | Applicable scheduled-formulation manufacturer | Form IV, Schedule II | At least six months beforehand |
| Display price lists | Retailers and dealers | DPCO paragraph 24(4) | At the business premises |
A company should not assume that it must file every form listed above. The requirement depends on the product and the applicable statutory provision.
GST and Maximum Retail Price Under the NPPA Notifications
The prices notified in the November 2026 orders are exclusive of applicable Goods and Services Tax.
This does not mean manufacturers can add any amount of tax they choose.
The orders allow GST to be added subject to the relevant statutory conditions, including whether the tax has actually been paid or is payable to the government.
How Is the MRP of a Medicine Pack Calculated?
A notified price may be stated for one tablet, capsule, millilitre, vial, strip or gram.
The price of the complete retail pack must be determined according to the applicable provisions of DPCO 2013, including paragraph 11 where relevant.
Manufacturers need to check the specified pricing unit and the actual pack details before determining the final MRP.
For example, a price notified per millilitre is not the same as the price of an entire bottle. The pack price must be determined using the applicable pricing rules and the actual quantity.
The notification must also be checked for any specific conditions affecting the product.
Can a Company Sell Below the Notified Price?
The answer depends on the type of order and the governing provisions.
According to the ceiling-price notification for oxaliplatin, existing manufacturers who have their MRPs below the notified ceiling price along with GST should retain their low MRPs according to clause 13(2) of DPCO 2013.
Other situations must be examined under the relevant retail-price order and DPCO provisions. Companies should not assume that all NPPA price notifications contain identical conditions.
Responsibilities of Drug Retailers and Distributors
The November notifications also refer to the responsibilities of businesses selling medicines.
Under paragraph 24(4) of DPCO 2013, retailers and dealers must display the price lists and supplementary price lists supplied by manufacturers in a conspicuous and accessible part of their premises.
The purpose is to make the relevant pricing information available to people who wish to consult it.
Retailers should also check that the prices charged for affected products comply with the applicable legal requirements.
For distributors, keeping updated manufacturer price lists and communicating relevant changes can help avoid pricing differences across the supply chain.
What Happens If Pharmaceutical Companies Do Not Follow NPPA Prices?
Drug price controls are legally binding where the relevant provisions apply.
A manufacturer or marketing company that charges more than the permitted price may face recovery proceedings under DPCO 2013, read with the Essential Commodities Act, 1955.
Recovery of Overcharged Amounts
The November orders state that concerned manufacturers or marketing companies failing to follow the notified price conditions may be required to deposit the overcharged amount.
The recoverable amount depends on the actual overcharging and the applicable law.
Interest on Overcharged Amounts
Interest may also be payable on the amount overcharged.
The notifications refer to recovery of the overcharged amount along with interest under the relevant statutory framework.
Other Legal Consequences
Other legal consequences may arise where the conditions of the applicable law are met.
However, the notifications do not establish one fixed automatic penalty for every pricing error. Any additional action must be assessed under the relevant legal provisions and the facts of the case.
What Should Pharmaceutical Businesses Do After the NPPA Notification?
Businesses dealing with the medicines listed in the November orders should check their products and determine whether any pricing or reporting action is required.
The following checklist may help.
| Check | Suggested action | Why it matters |
| Product identity | Match full formulation, strength and dosage | Avoid applying a price to the wrong medicine |
| Company applicability | Check manufacturer and marketing company | Establish the order's scope |
| Price and unit | Compare notified price with product pricing | Identify any required revisions |
| GST and pack MRP | Apply the relevant DPCO rules | Avoid incorrect pack pricing |
| Price-list filing | Review Form V requirements | Meet applicable reporting duties |
| New-drug launch | Assess Form IA conditions | Address eligible launches under S.O. 5998(E) |
| Scheduled-formulation reporting | Review Form III and Form IV obligations | Meet relevant reporting requirements |
| Retail distribution | Communicate accurate price lists | Keep price information consistent |
For businesses searching for NPPA compliance services, the initial assessment should be product-specific rather than a generic filing exercise.
The first step is to identify whether the business deals with a covered formulation.
If a product is covered, the company should check the price and conditions in the relevant order. This is particularly important where one company manufactures the medicine and another markets it.
Businesses should also review existing internal pricing procedures and ensure that the responsible teams have access to the applicable notification.
How Corpseed Can Help?
Pharmaceutical businesses must meet the regulatory requirements applicable to their products and activities. These may include drug licensing, registration, documentation and other approvals, depending on the business.
Corpseed provides professional assistance with pharmaceutical regulatory services. Businesses can seek support for relevant approvals and documentation requirements based on their operations.
Pharmaceutical regulatory compliance services may include drug licence registration services, CDSCO registration support and documentation assistance, subject to the scope of the provider. Specialised NPPA price-filing or IPDMS work should be confirmed separately before engagement.
Drug Licence Registration
Businesses involved in pharmaceutical manufacturing, distribution or sale may require the appropriate drug licences.
Corpseed assists with drug licence registration and related application requirements within its service scope.
CDSCO Registration Support
Certain pharmaceutical products and business activities require registration or approval from the Central Drugs Standard Control Organization (CDSCO).
Corpseed assists with relevant CDSCO registration and approval processes.
Pharmaceutical Regulatory Documentation
The process of regulation requires proper information and documentation. Corpseed provides its pharmaceutical regulatory services by helping organizations to prepare their documentation.
For specialised NPPA pricing and IPDMS filing requirements, businesses should confirm the exact scope of available professional support before engaging a consultant.
Need assistance with pharmaceutical regulatory approvals or related compliance requirements? Contact Corpseed to discuss the support relevant to your business.
Key Takeaways
The drug price notification notices by the NPPA dated November 2026 contain 35 retail price notifications, a revision of the ceiling price of Oxaliplatin injection, and amendments to a previous pricing notice.
Manufacturing companies and marketing firms that are involved with the mentioned formulations must look into the above-noted price notifications.
The relevant DPCO provisions also contain requirements for price lists, reporting and other compliance matters. Businesses should identify which obligations apply to their products rather than treating all notifications as identical.
Schedule a Call Back
Document Preview
Embedded reference document
